David Sallman, MD, Moffitt Cancer Center, discussed the trial's impact and the future role of MRD monitoring in treatment ...

Experts discuss the comparative efficacy of sonrotoclax plus zanubrutinib vs venetoclax in chronic lymphocytic leukemia ...

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...

Panelists discuss how guideline-recommended treatment regimens for patients with transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma should be evaluated and selected based on ...

During the 66th American Society of Hematology Annual Meeting and Exposition, investigators revealed early-phase 1 data evaluating various BTK degraders that leverage different strategies to overcome ...

Thomas W. LeBlanc, MD, MA, discusses how erythroid maturation agents (EMAs), such as luspatercept, are increasingly important in the anemia management landscape for low-risk myelodysplastic syndromes ...

BCL-2 inhibitors, such as venetoclax (Venclexta) work by targeting the BCL-2 protein, which plays a key role in preventing ...

Panelists discuss the INSEMA trial, comparing no axillary surgery versus axillary sentinel lymph node biopsy (SLNB) in patients with early invasive breast cancer, exploring the implications for ...

Joe DePinto, MBA, discussed the findings of the McKesson 2024 Cell and Gene Therapy Report, providing insight into the ...

Invikafusp alfa has gained FDA fast track designation for treating TMB-H metastatic colorectal cancer. Invikafusp alfa ...

Panelists discuss the exploratory biomarker analysis from the KEYNOTE-522 trial, comparing perioperative pembrolizumab versus placebo plus chemotherapy in early-stage breast cancer, and its ...